Jan 21, 2026

AD Biomarker

DOI
https://dx.doi.org/10.17504/protocols.io.bp2l6dop5vqe/v1
  • Abhay Moghekar1
  • 1Johns Hopkins University
  • Abhay Moghekar: On behalf of the Precision Aging Network
Joel Parker
Icon indicating open access to content
QR code linking to this content
DOI: https://dx.doi.org/10.17504/protocols.io.bp2l6dop5vqe/v1
Protocol Citation: Abhay Moghekar 2026. AD Biomarker . protocols.io https://dx.doi.org/10.17504/protocols.io.bp2l6dop5vqe/v1
License: This is an open access  protocol  distributed under the terms of the  Creative Commons Attribution License,  which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: March 11, 2025
Last Modified: January 21, 2026
Protocol  Integer ID: 124196
Keywords: quantitative plasma biomarker measurement, biomarker, key biomarker, neurodegenerative disease, including alzheimer, simoa neuro, general brain health panel, advanced digital immunoassay, abeta1
Funders Acknowledgements:
Precision Aging Network
Grant ID: U19AG065169
Abstract
The general brain health panel provides quantitative plasma biomarker measurements commonly associated with neurodegenerative diseases, including Alzheimer’s. These
biomarkers are quantified using two advanced digital immunoassays. The Simoa Neuro 4-Plex E assay measures concentrations of four key biomarkers: Abeta1-40, Abeta 1-42, GFAP, and NF-light. Additionally, the Simoa Human pTau-181 Advantage assay specifically quantifies pTau-181.
SOP
Download Johns Hopkins Testing SOPV1.pdfJohns Hopkins Testing SOPV1.pdf

Data
Description: The general brain health panel provides quantitative plasma biomarker measurements commonly associated with neurodegenerative diseases, including Alzheimer’s. These biomarkers are quantified using two advanced digital immunoassays. The Simoa Neuro 4-Plex E assay measures concentrations of four key biomarkers: Abeta 1-40, Abeta 1-42, GFAP, and NF-light. Additionally, the Simoa Human pTau-181 Advantage assay specifically quantifies pTau-181.
Data: Duplicate concentrations of each biomarker, measured in picograms per milliliter (pg/mL), are measured for each sample. The mean of the two replicate measurements for each biomarker are reported in the {biomarkername} columns. The {biomarkername}_SD_5 columns are the calculated 5*SDs from the mean for each biomarker based on the mean over all PAN participants.